Page last updated: 2024-12-09

1H-benzimidazole-5,6-diamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1H-benzimidazole-5,6-diamine: A Versatile Building Block for Research

1H-benzimidazole-5,6-diamine is a **heterocyclic organic compound** with the molecular formula C7H9N3. It's essentially a benzimidazole ring with two amine groups (NH2) attached at positions 5 and 6.

**Why is it important for research?**

1H-benzimidazole-5,6-diamine is a valuable starting material and building block in various research fields due to its **versatility and potential for diverse applications**:

* **Pharmaceutical Research:**
* **Anti-cancer Activity:** The compound has shown promise as a potential anti-cancer agent. Its ability to inhibit the growth of cancer cells has been studied in different cancer types, including leukemia and breast cancer.
* **Antimicrobial Activity:** Benzimidazole derivatives, including 1H-benzimidazole-5,6-diamine, have exhibited antimicrobial properties against a wide range of bacteria and fungi.
* **Anti-inflammatory Activity:** The compound has demonstrated potential anti-inflammatory effects, offering promise in treating various inflammatory conditions.
* **Materials Science:**
* **Organic Electronics:** Benzimidazole derivatives, particularly those with amine groups, can be incorporated into organic electronic materials. These materials are used in applications like organic light-emitting diodes (OLEDs) and organic solar cells.
* **Polymer Synthesis:** 1H-benzimidazole-5,6-diamine can serve as a monomer for the synthesis of various polymers, which can find uses in different fields like biomedicine and materials science.
* **Dye and Pigment Development:** The compound can be used as a starting material for the synthesis of various dyes and pigments with applications in textiles, printing, and coloring materials.

**Key Properties:**

* **Reactivity:** The amine groups on 1H-benzimidazole-5,6-diamine make it highly reactive, enabling it to undergo various chemical transformations, leading to diverse derivatives with tailored properties.
* **Optical Properties:** Benzimidazole derivatives often exhibit interesting optical properties, like fluorescence and phosphorescence, which are crucial for various applications in imaging, sensing, and lighting.

**Overall, 1H-benzimidazole-5,6-diamine is a highly versatile compound with significant potential for research in diverse fields like pharmaceutical development, materials science, and organic chemistry.** Its unique properties and reactivity make it an attractive starting material for the development of novel compounds with promising applications.

**Note:** It's important to remember that research is ongoing and the specific applications and potential of 1H-benzimidazole-5,6-diamine are still under investigation.

Cross-References

ID SourceID
PubMed CID2773193
CHEMBL ID1589385
CHEBI ID107392
SCHEMBL ID4370465
SCHEMBL ID5270917

Synonyms (30)

Synonym
EU-0010117
LS-12758
HMS2639F10
OPREA1_248651
MLS000724043 ,
smr000305638
1h-benzimidazole-5,6-diamine
CHEBI:107392
AKOS000365695
FT-0666353
A837115
71209-21-7
1h-benzo[d]imidazole-5,6-diamine
HMS3364E08
5,6-diaminobenzimidazole trihydrochloride
SJVPHAOWYMKBPE-UHFFFAOYSA-N
5,6-diamino-1h-benzo[d]imidazole
5,6-diaminobenzimidazole
SCHEMBL4370465
CHEMBL1589385
SCHEMBL5270917
bdbm34936
(6-amino-1h-benzimidazol-5-yl)amine
cid_2773193
Q27185699
1h-1,3-benzodiazole-5,6-diamine
D95042
CS-0117064
DTXSID201327877
EN300-1588743
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency79.43280.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency0.44560.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency2.29830.125919.1169125.8920AID2549; AID2708
LuciferasePhotinus pyralis (common eastern firefly)Potency15.10140.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency1.12200.01846.806014.1254AID624417
WRNHomo sapiens (human)Potency56.23410.168331.2583100.0000AID651768
ATAD5 protein, partialHomo sapiens (human)Potency11.57740.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency24.51920.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency18.25630.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency28.18380.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency10.00000.540617.639296.1227AID2528
importin subunit beta-1 isoform 1Homo sapiens (human)Potency39.81075.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency39.81075.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency95.28340.425612.059128.1838AID504891
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency9.20000.004611.374133.4983AID624297
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency44.66840.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency44.66840.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency44.66840.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency44.66840.01418.602439.8107AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)54.00000.40007.134454.0000AID1417
MPI proteinHomo sapiens (human)IC50 (µMol)50.00000.190013.825650.1000AID1220
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
mitogen-activated protein kinase kinase kinase kinase 2 isoform 1Homo sapiens (human)EC50 (µMol)8.31500.67008.534426.3600AID1895; AID1897
mitogen-activated protein kinase kinase kinase 3 isoform 1Homo sapiens (human)EC50 (µMol)7.87002.68006.670011.8600AID1896
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)EC50 (µMol)10.74000.00543.251020.9400AID1897
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]